ABSTRACT
We present the design and development of a data visualization service (RAMPVIS) in response to the urgent need to support epidemiological modeling workflows during the COVID-19 pandemic. Facing a set of demanding requirements and several practical challenges, our small team of volunteers had to rely on existing knowledge and components of services computing, while thinking on our feet in configuring services composition and adopting suitable approaches to services engineering. Through developing the RAMPVIS service, we have gained useful experience of ensuring conformation to services computing standards, enabling rapid development and early deployment, and facilitating effective and efficient maintenance and operation with limited resources. This experience can be valuable to the ongoing effort for combating the COVID-19 pandemic, and provides a blueprint for visualization service development when future needs for visual analytics arise during emergency response. IEEE
ABSTRACT
The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on "Vaccine Stability Considerations to Enable Rapid Development and Deployment", on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the industry, academia, regulatory agencies, as well as health care leaders. This paper presents a review of the topics covered. Specifically the challenges in accelerating vaccine development and analytical characterization techniques to establish shelf-life were covered. Additionally, vaccine stability modeling using prior knowledge stability models and advanced kinetic analysis played a key in the EUA approaches discussed during the workshop. Finally, the role of stability studies in addressing the challenges of vaccine distribution and deployment during the pandemic were a focus of presentations and panel discussions. Although the workshop did not have any presentation topics directly dedicated to the mRNA vaccines, the techniques discussed are generally applicable. The mRNA vaccine developers were represented in the panel discussions, where experts involved in the EUA approval/deployment stages for this vaccine type could discuss the challenges as applied to their vaccines.
ABSTRACT
Given supply constraints of N95s in the United States during the COVID-19 pandemic, healthcare facilities have turned to extended use protocols and new sources of N95s. Because fit testing every employee for every new mask is not feasible, our Infection Prevention Department developed a method for rapid deployment of new N95s.